Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE 76 versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE 76 versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
HYPAQUE-76 vs IOPAMIDOL-250 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-76 (diatrizoate meglumine and diatrizoate sodium) is an ionic iodinated contrast agent that attenuates X-rays, providing radiographic contrast. Its mechanism involves high iodine content (76%) that absorbs X-rays, distinguishing anatomical structures in imaging procedures.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
Intravenous: 50-100 mL (as a 76% solution, 370 mg iodine/mL) for contrast imaging, administered as a bolus or infusion; maximum 300 mL per procedure.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
None Documented
None Documented
Terminal elimination half-life of 1.5-2 hours in normal renal function. Prolonged to >10 hours in moderate renal impairment (CrCl 30-50 mL/min). Closely correlates with creatinine clearance.
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Primarily renal; >95% excreted unchanged in urine within 24 hours via glomerular filtration. Fecal excretion minimal (<5%). Biliary excretion negligible.
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent